Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of ...

Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive ...

“We look forward to advancing CTIM-76 toward target dose levels in 2025," commented Claudio Dansky Ullmann, M.D., Chief Medical Officer of Context.

Tiziana Life Sciences (TLSA) announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue ...

The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

AbCellera announced that it has expanded its existing collaboration with AbbVie Inc. to include the discovery of T-cell ...

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...

GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications ...

Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and ...